Proline-rich tyrosine kinase 2 (Pyk2) is a cytoplasmic, non-receptor tyrosine kinase implicated in multiple signaling pathways.Direct receptor-receptor interactions involving Ig-like domain 4 stabilize the receptor dimerization, which is primarily caused by ligand binding to Ig-like domains 2 and 3.The juxtaposition of the intracellular components during dimerization, which encourages autophosphorylation in trans between the receptors, is a crucial step in activation. The phosphorylated PDGFR then recruits molecules with SH2 domains like Src kinase, Grb2, SHP2, PLC, Nck, and STAT to start various downstream signaling events.
More than 60% of hepatocellular carcinoma (HCC) patients' tumors have elevated levels of Pyk2, a FAK family non-receptor tyrosine kinase.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69741 | NCGC00188636 | 1039980-33-0 | NCGC00188636 is a novel covalent pyruvate kinase (PYK) inhibitor. |
|
V8608 | PF-4618433 | 1166393-85-6 | PF-4618433 is a novel, potent and selective inhibitor of proline-rich tyrosine kinase 2 (PYK2) and focal adhesion kinase (FAK), showing improved PYK2 potency, reduced p38 activity, and superior overall selectivity relative to the prototype BIRB796. |
|
V88024 | Pyk2-IN-2 | Pyk2-IN-2 (compound 13j) is an inhibitor of Pyk2 with IC50 of 0.608 μM for FAK kinase. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
